News Sentiment

SGMT sentiment intelligence

Sagimet Biosciences Inc. Series A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.37 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-3.2% over one week, +13.7% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend active 13.7% over four weeks
Fair value 22.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 51
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 11
TradingView 8
GlobeNewswire 7
The Globe and Mail 4
simplywall.st 4
TipRanks 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 20
Analyst action 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 67
The Globe and Mail Direct company coverage

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT)

Two healthcare stocks, Intellia Therapeutics (NTLA) and Sagimet Biosciences, Inc. Class A (SGMT), have received bullish sentiments from analysts. Leerink Partners reiterated a Buy rating on Intellia Therapeutics with a $35.00 price target, while Wedbush analyst Yun Zhong maintain

Tone
Positive 73/100
Event
Analyst action
Published
02 May 2026 10:09
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO)

This article summarizes recent analyst ratings for three healthcare companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK), and Crescent Biopharma (CBIO). Analysts from Guggenheim, Bank of America Securities, and Piper Sandler maintained Buy or Hold ratings and provided spec

Tone
Neutral 50/100
Event
Analyst action
Published
02 May 2026 04:39
Source
The Globe and Mail
TipRanks Direct company coverage

Sagimet Biosciences Announces Major Equity Offering for Pipeline

Sagimet Biosciences announced an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expected to yield $164.5 million in net proceeds. This capital infusion will fund a Phase 3 clinical trial of denifanstat in acne, advance TVB-3567,

Tone
Positive 67/100
Event
Market update
Published
28 Apr 2026 11:39
Source
TipRanks
Stock Titan Direct company coverage

Sagimet raises $175M, says cash now funds acne programs through 2028

Sagimet Biosciences (Nasdaq: SGMT) priced an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, resulting in gross proceeds of approximately $175.0 million. The company intends to use the net proceeds to fund a Phase 3 denifanstat acne trial, advance T

Tone
Positive 66/100
Event
Balance sheet
Published
28 Apr 2026 03:39
Source
Stock Titan
Quiver Quantitative Direct company coverage

Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million

Sagimet Biosciences Inc. has announced the pricing of an underwritten offering of 29,166,700 shares of Series A common stock at $6.00 per share, aiming to raise approximately $175 million. The funds are earmarked for funding a Phase 3 clinical trial for denifanstat in acne, advan

Tone
Positive 62/100
Event
Market update
Published
27 Apr 2026 11:20
Source
Quiver Quantitative
Market source Direct company coverage

Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans

Sagimet Biosciences (NASDAQ:SGMT) saw its shares jump 30% after announcing plans for a Phase 3 clinical trial in the U.S. for its acne treatment, denifanstat, to commence in the second half of 2026. The company is prioritizing its dermatology portfolio, supported by positive Phas

Tone
Positive 80/100
Event
Market update
Published
27 Apr 2026 11:13
Source
Market source
Stock Titan Direct company coverage

Sagimet turns to two-decade drug veteran after its medical chief retires

Sagimet Biosciences (Nasdaq: SGMT) has appointed Andreas Grauer, MD, as its new Chief Medical Officer, effective April 20, 2026. Dr. Grauer brings over two decades of global clinical development experience, replacing Eduardo Bruno Martins, MD, DPhil, who has retired but will cont

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 03:39
Source
Stock Titan